Amol Padgaonkar

Discovery of 8-Cyclopentyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-7-oxo-7,8-dihydro-pyrido[2,3-<i>d</i>]pyrimidine-6-carbonitrile (<b>7x</b>) as a Potent Inhibitor of Cyclin-Dependent Kinase 4 (CDK4) and AMPK-Related Kinase 5 (ARK5)

M. V. Ramana Reddy, Balireddy Akula, Stephen C. Cosenza et al. · Journal of Medicinal Chemistry · 2014 · 71 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +15

Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease

Katsutoshi Sato, Amol Padgaonkar, Stacey J. Baker et al. · Nature Communications · 2021 · 63 citations · Full text

Medicine, Cancer Biology, Oncology +17

Design, Synthesis, and Biological Evaluation of (<i>E</i>)-<i>N</i>-Aryl-2-arylethenesulfonamide Analogues as Potent and Orally Bioavailable Microtubule-Targeted Anticancer Agents

M. V. Ramana Reddy, Muralidhar R. Mallireddigari, Venkat R. Pallela et al. · Journal of Medicinal Chemistry · 2013 · 24 citations · Full text

Medicine, Oncology, Pharmacology +14

Cyclin-dependent kinase inhibitor, P276-00, inhibits HIF-1α and induces G2/M arrest under hypoxia in prostate cancer cells

Sonal M. Manohar, Amol Padgaonkar, Archana Jalota‐Badhwar et al. · Prostate Cancer and Prostatic Diseases · 2011 · 22 citations

Medicine, Cancer Biology, Oncology +15

A novel inhibitor of hypoxia-inducible factor-1α P3155 also modulates PI3K pathway and inhibits growth of prostate cancer cells

Sonal M. Manohar, Amol Padgaonkar, Archana Jalota‐Badhwar et al. · BMC Cancer · 2011 · 21 citations · Full text

Medicine, Oncology, Pharmacology +17